CSW Bronchiolitis Pathway Team for December 7, 2020, Go-Live

Total Page:16

File Type:pdf, Size:1020Kb

CSW Bronchiolitis Pathway Team for December 7, 2020, Go-Live Bronchiolitis Pathway v12.0: Table of Contents Inpatient & ED Inclusion Criteria · Age <2 years · Prematurity and/or age <12 weeks may be included, but expect a more severe course of illness Stop and · Viral upper respiratory symptoms & lower respiratory symptoms Review that may include: increased work of breathing, cough, feeding difficulty, tachypnea, wheeze, fever Inpatient & ED Exclusion Criteria · Cardiac disease requiring baseline medication · Anatomic airway defects · Neuromuscular disease · Immunodeficiency · Chronic lung disease HFNC Inclusion Criteria · Primary diagnosis of bronchiolitis · Age 44 weeks PMA to <2 years · ONE of the following: Stop and 1) Severe respiratory distress (deep retractions in multiple areas, Review grunting, head bobbing), or 2) Significant hypoxia (need for >1 lpm NCO2 if 30-90 days, >1.5 lpm for 91 days – 6 months, >2 lpm for 6 months – 2 years) HFNC Exclusion Criteria · Concern for impending respiratory failure (lethargy, poor perfusion, apnea) · Primary diagnosis of pneumonia, asthma, or croup · Born prematurely <34 weeks (if <6 mo) · History of intubation for respiratory failure · Cardiac disease requiring baseline medication · Anatomic airway defects · Neuromuscular disease · Immunodeficiency · Chronic lung disease Bronchiolitis Care Criteria & Respiratory Score ED Management Inpatient Phase HFNC Phase Appendix Version Changes Approval & Citation Evidence Ratings Bibliography For questions concerning this pathway, contact: Last Updated: December 2020 [email protected] Next Expected Review: December 2025 If you are a patient with questions contact your medical provider, Medical Disclaimer © 2020 Seattle Children’s Hospital, all rights reserved Bronchiolitis Pathway v12.0: Criteria and Respiratory Score Inclusion Criteria · Age <2 years · Prematurity and/or age <12 weeks may be included, but expect a more severe course of illness Stop and · Viral upper respiratory symptoms & lower respiratory symptoms Review that may include: increased work of breathing, cough, feeding difficulty, tachypnea, wheeze, fever Exclusion Criteria · Cardiac disease requiring baseline medication · Anatomic airway defects · Neuromuscular disease · Immunodeficiency · Chronic lung disease RESPIRATORY SCORE (RS) Variable 0 points 1 point 2 points 3 points RR <2 mo ≤60 61-69 ≥70 2-12 mo ≤50 51-59 ≥60 1-2 yr ≤40 41-44 ≥45 Retractions None Subcostal or intercostal 2 of the following: 3 of the following: subcostal, subcostal, intercostal, intercostal, substernal, substernal, OR nasal suprasternal, supraclavicular OR flaring (infant) nasal flaring / head bobbing (infant) Dyspnea 0-2 years Normal feeding, 1 of the following: difficulty 2 of the following: difficulty Stops feeding, no vocalization or vocalizations and activity feeding, decreased feeding, decreased drowsy and confused vocalization or agitated vocalization or agitated Auscultation Normal breathing, no End-expiratory wheeze only Expiratory wheeze only Inspiratory and expiratory wheezing present (greater than end- wheeze OR diminished breath expiratory wheeze) sounds OR both For questions concerning this pathway, contact: Last Updated: December 2020 [email protected] Next Expected Review: December 2025 If you are a patient with questions contact your medical provider, Medical Disclaimer © 2020 Seattle Children’s Hospital, all rights reserved Bronchiolitis Pathway v12.0: ED Management Inclusion Criteria · Age <2 years Therapies NOT · Prematurity and/or age <12 weeks may be included, but expect a more severe course of illness routinely Stop and · Viral upper respiratory symptoms & lower respiratory symptoms recommended Review that may include: increased work of breathing, cough, feeding difficulty, tachypnea, wheeze, fever · Albuterol · Racemic Exclusion Criteria Epinepherine · Cardiac disease requiring baseline medication · Corticosteroids · Anatomic airway defects · Chest Physiotheraphy · Neuromuscular disease · Montelukast · Immunodeficiency · Antibotics · Chronic lung disease · Hypertonic Saline Urgent Care Transfer Criteria · Severe respiratory distress after suction and reevaluation · Inadequate oral hydration ! ! · Hypoxemia · Apnea Routine testing Chest X-rays · Signs of clinical deterioration for viral pathogens NOT routinely NOT recommended recommended *Transport via ALS unless for cohorting Initial assessment Considerations for severely ill patients · SCORE, SUCTION, SCORE: nasal suction; follow with NP · May consider ONE-TIME albuterol MDI trial if: suction if needed · Severe respiratory distress OR · Provide supplemental O2 to keep saturation >90% (>88% · Worsening respiratory distress PLUS increased risk for asleep). Start at ½ L and titrate as needed. asthma (>12 months old, wheeze, and one of the following: personal history of atopy or recurrent wheezing OR strong family history of atopy or asthma) Rehydration · Continue albuterol PRN ONLY if improves work of breathing · Give supplemental NG or IV fluids if moderately to · Consider HFNC for significant hypoxia OR severe respiratory severely dehydrated; NPO and IV fluids if severe distress not improving with rigorous supportive care (suction, respiratory distress hydration, antipyretics, standard NC) · Encourage NG over IV fluids, esp. if <1 year old · If safe for PO feeds and mildly to moderately dehydrated, attempt oral feeding Go to HFNC Phase Family teaching · Viral illness, treated by hydration and suction · Signs of respiratory distress · When and how to suction · Frequent feeds and watch hydration status · Cough may last 2-4 weeks, do not use OTC cough and cold medications, avoid tobacco smoke Suction and reevaluation · Respiratory score (SCORE, SUCTION, SCORE) Q 1 hour + prn if mild to moderate distress Discharge Decision to Admit or Able to · Respiratory score and suction q30 minutes + prn if severe Recommend follow Discharge discharge respiratory distress up in 24-48 hours · For patients with prolonged ED stays, may space suctioning per MD discretion Medical Unit Admit Criteria ICU Admit Criteria (any of the following) (any of the following) · Sustained hypoxemia (SpO2 <90% awake, · Clinical worsening despite floor max HFNC 88% asleep) support · Apnea · Desaturations below 90% despite 50% FiO2 · Dehydration/impaired oral hydration requiring · Other late findings of respiratory failure: ongoing IV or NG fluids · Inappropriately low respiratory rate with · HFNC trial initiated, clinically improved or worsening obstruction unchanged · Lethargy despite noxious stimuli · Moderate to severe respiratory distress AND · Poor perfusion one of the above criteria · Apnea >20 seconds with associated bradycardia/desaturation requiring intervention For questions concerning this pathway, contact: Last Updated: December 2020 [email protected] Next Expected Review: December 2025 If you are a patient with questions contact your medical provider, Medical Disclaimer © 2020 Seattle Children’s Hospital, all rights reserved Bronchiolitis Pathway v12.0: Inpatient Management Inclusion Criteria · Age <2 years Therapies NOT · Prematurity and/or age <12 weeks may be included, but expect a more severe course of illness routinely Stop and · Viral upper respiratory symptoms & lower respiratory symptoms recommended Review that may include: increased work of breathing, cough, feeding difficulty, tachypnea, wheeze, fever · Albuterol · Racemic Exclusion Criteria Epinepherine · Cardiac disease requiring baseline medication · Corticosteroids · Anatomic airway defects · Chest Physiotheraphy · Neuromuscular disease · Montelukast · Immunodeficiency · Antibotics · Chronic lung disease · Hypertonic Saline Patient admitted ! Signs of clinical Begin family teaching deterioration: · Signs of respiratory distress · How to suction · When to suction Lethargy despite noxious stimuli, inappropriately low respiratory rate with worsening · Assess patient obstruction, apnea, poor perfusion; · Calculate respiratory score Deterioration does not correlate with day of illness · Place CR monitors · Notify MD · Call Rapid Response Team Pre-suction score is LOW (1-4) Pre-suction score is MODERATE (5-8) Pre-suction score is HIGH (9-12) · Score, Suction, Score minimum · Score minimum q 2 hours · Score minimum q 1 hours q4 hours, prior to feeds or if · Suction minimum q2-4 hours. Score after · Suction minimum q2-4 hours. Score more distressed suctioning. after suctioning. · Nasal suction · Nasal suction · Nasal suction · No continuous pulse oximetry · NP suction if clinically indicated for work of · NP suction if clinically indicated for work · If on NG/IV fluids, discontinue breathing after nasal suctioning of breathing after nasal suctioning fluids and restart oral feeds · Spot SpO2 checks; continuous pulse · Continuous pulse oximetry oximetry if on supplemental O2 or per care · Consider albuterol trial and HFNC trial team request due to clinical concerns (see below) · Rescore at interval specified above (either 1, 2, or 4 hours) · Recategorize based on pre-suction score Ready for discharge? Inadequate PO Intake Discharge Criteria Escalation for worsening patients · Encourage NG over IV fluids, · May consider ONE-TIME albuterol especially if <1 year old Patients should be meet ALL of the trial (only if not previously trialed) if: · NPO and IV fluids if severe following criteria: · Severe respiratory distress OR respiratory distress · Respiratory score <5 for at least 8 hours · Worsening respiratory distress · No need for NP suctioning for 4 hours PLUS increased risk for asthma · Off supplemental
Recommended publications
  • Caring for Children with Special Needs ALLERGIES and ASTHMA
    caring for children with special needs ALLERGIES AND ASTHMA We don’t usually think of children with allergies or asthma as children with “special needs,” but they certainly are. In fact, children with these conditions are probably the most frequently encountered “special needs” children. Child care providers can do a great deal to help individual children manage their specific allergy or asthma needs and feel more comfortable in a child care setting. Allergies wastes. Every house has them, no matter how clean. Other inhaled Children with allergies face the allergens include mold, pollen (hay same social difficulties as do adults, fever), animal dander (especially but they have less maturity and from cats), chemicals, and per­ emotional resources to deal with fumes. them. Children find that they cannot eat what their friends eat or The most common allergy symp­ cannot play outside during some toms are seasons. Until a child is mature � a clear, runny nose and enough to understand why she sneezing, cannot do something, you must be � itchy or stuffed-up nose or careful to help the child through the itchy, runny eyes, and difficulties. Start teaching a child early on about what he is allergic to; � asthma (remember that not all you will not always be able to people with asthma have monitor everything. allergies and not all allergies Some foods can cause a life­ cause or develop into asthma). threatening reaction. The mouth, throat, and bronchial tubes swell enough to interfere with breathing. Strategies for inclusion The person may wheeze or faint. Some parents have found that by Often there are generalized hives volunteering to bring food to and/or a swollen face.
    [Show full text]
  • Symptoms Related to Asthma and Chronic Bronchitis in Three Areas of Sweden
    Eur Respir J, 1994, 7, 2146–2153 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07122146 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Symptoms related to asthma and chronic bronchitis in three areas of Sweden E. Björnsson*, P. Plaschke**, E. Norrman+, C. Janson*, B. Lundbäck+, A. Rosenhall+, N. Lindholm**, L. Rosenhall+, E. Berglund++, G. Boman* Symptoms related to asthma and chronic bronchitis in three areas of Sweden. E. Björnsson, *Dept of Lung Medicine and Asthma P. Plaschke, E. Norrman, C. Janson, B. Lundbäck, A. Rosenhall, N. Lindholm, L. Research Center, Akademiska sjukhu- Rosenhall, E. Berglund, G. Boman. ERS Journals Ltd 1994. set, Uppsala University, Uppsala, Sweden. ABSTRACT: Does the prevalence of respiratory symptoms differ between regions? **Asthma and Allergy Research Center, Sahlgren's Hospital, University of Göteborg, As a part of the European Community Respiratory Health Survey, we present data Göteborg, Sweden. +Dept of Pulmonary from an international questionnaire on asthma symptoms occurring during a 12 Medicine and Allergology, Univer- month period, smoking and symptoms of chronic bronchitis. The questionnaire was sity Hospital of Northern Sweden, Umeå, mailed to 10,800 persons aged 20–44 yrs living in three regions of Sweden (Västerbotten, Sweden. ++Dept of Pulmonary Medicine, Uppsala and Göteborg) with different environmental characteristics. The total Sahlgrenska University Hospital, Göteborg, response rate was 86%. Sweden. Wheezing was reported by 20.5%, and the combination of wheezing without a Correspondence: E. Björnsson, Dept of cold and wheezing with breathlessness by 7.4%. The use of asthma medication was Lung Medicine, Akademiska sjukhuset, S- reported by 5.3%.
    [Show full text]
  • What Is Asthma? Figure 1
    American Thoracic Society PATIENT EDUCATION | INFORMATION SERIES What Is Asthma? Figure 1. Normal Airway Figure 2. Acute Asthma Asthma is a chronic disease that affects the airways of your lungs. Your airways are the breathing tubes that carry air in and out of your Muscle spasm causing lungs. There are two main problems in asthma: relaxed narrowing muscles swelling and increased mucus (inflammation) of airways in the airways, and squeezing of the muscles Mucus build up around the airways (bronchospasm). These open airways Swelling/inammation problems can make it hard to breathe. Taking medicines and avoiding things that trigger asthma can help control asthma. This fact sheet will address the basics of asthma—what it is, how it is diagnosed, and what are some common triggers. For information on treatment, see part 2, “Treatment of Asthma”. How do I know if I have asthma? function test–PFT) helps confirm the diagnosis. This test Common symptoms of asthma include: can detect narrowing (obstruction) in the airways. A normal breathing test result does not mean you do not have ■ Cough—often dry and can have harsh bursts asthma. Your healthcare provider may recommend other ■ Wheezing—a whistling sound mainly when you breathe types of testing to look for asthma. For more information out through narrowed airways about pulmonary function testing, see ATS Patient ■ Chest tightness Information series at www.thoracic.org/patients. ■ Shortness of breath which may occur with activity or If you have been diagnosed with asthma, but it is not even at rest getting better with treatment, you might benefit from When you are having a problem with asthma, you may feel CLIP AND COPY AND CLIP seeing an asthma specialist.
    [Show full text]
  • Problems in Family Practice
    problems in Family Practice Coughing in Childhood Hyman Sh ran d , M D Cambridge, M assachusetts Coughing in childhood is a common complaint involving a wide spectrum of underlying causes which require a thorough and rational approach by the physician. Most children who cough have relatively simple self-limiting viral infections, but some may have serious disease. A dry environment, allergic factors, cystic fibrosis, and other major illnesses must always be excluded. A simple clinical approach, and the sensible use of appropriate investigations, is most likely to succeed in finding the cause, which can allow precise management. The cough reflex as part of the defense mechanism of the respiratory tract is initiated by mucosal changes, secretions or foreign material in the pharynx, larynx, tracheobronchial Table 1. Persistent Cough — Causes in Childhood* tree, pleura, or ear. Acting as the “watchdog of the lungs,” the “good” cough prevents harmful agents from Common Uncommon Rare entering the respiratory tract; it also helps bring up irritant material from Environmental Overheating with low humidity the airway. The “bad” cough, on the Allergens other hand, serves no useful purpose Pollution Tobacco smoke and, if persistent, causes fatigue, keeps Upper Respiratory Tract the child (and parents) awake, inter­ Recurrent viral URI Pertussis Laryngeal stridor feres with feeding, and induces vomit­ Rhinitis, Pharyngitis Echo 12 Vocal cord palsy Allergic rhinitis Nasal polyp Vascular ring ing. It is best suppressed. Coughs and Prolonged use of nose drops Wax in ear colds constitute almost three quarters Sinusitis of all illness in young children. The Lower Respiratory Tract Asthma Cystic fibrosis Rt.
    [Show full text]
  • Asthma Exacerbation Management
    CLINICAL PATHWAY ASTHMA EXACERBATION MANAGEMENT TABLE OF CONTENTS Figure 1. Algorithm for Asthma Exacerbation Management – Outpatient Clinic Figure 2. Algorithm for Asthma Management – Emergency Department Figure 3. Algorithm for Asthma Management – Inpatient Figure 4. Progression through the Bronchodilator Weaning Protocol Table 1. Pediatric Asthma Severity (PAS) Score Table 2. Bronchodilator Weaning Protocol Target Population Clinical Management Clinical Assessment Treatment Clinical Care Guidelines for Treatment of Asthma Exacerbations Children’s Hospital Colorado High Risk Asthma Program Table 3. Dosage of Daily Controller Medication for Asthma Control Table 4. Dosage of Medications for Asthma Exacerbations Table 5. Dexamethasone Dosing Guide for Asthma Figure 5. Algorithm for Dexamethasone Dosing – Inpatient Asthma Patient | Caregiver Education Materials Appendix A. Asthma Management – Outpatient Appendix B. Asthma Stepwise Approach (aka STEPs) Appendix C. Asthma Education Handout References Clinical Improvement Team Page 1 of 24 CLINICAL PATHWAY FIGURE 1. ALGORITHM FOR ASTHMA EXACERBATION MANAGEMENT – OUTPATIENT CLINIC Triage RN/MA: • Check HR, RR, temp, pulse ox. Triage level as appropriate • Notify attending physician if patient in severe distress (RR greater than 35, oxygen saturation less than 90%, speaks in single words/trouble breathing at rest) Primary RN: • Give oxygen to keep pulse oximetry greater than 90% Treatment Inclusion Criteria 1. Give nebulized or MDI3 albuterol up to 3 doses. Albuterol dosing is 0.15 to 0.3mg/kg per 2007 • 2 years or older NHLBI guidelines. • Treated for asthma or asthma • Less than 20 kg: 2.5 mg neb x 3 or 2 to 4 puffs MDI albuterol x 3 exacerbation • 20 kg or greater: 5 mg neb x 3 or 4 to 8 puffs MDI albuterol x 3 • First time wheeze with history consistent Note: For moderate (dyspnea interferes with activities)/severe (dyspnea at rest) exacerbations you with asthma can add atrovent to nebulized albuterol at 0.5mg/neb x 3.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • The Effects of Inhaled Albuterol in Transient Tachypnea of the Newborn Myo-Jing Kim,1 Jae-Ho Yoo,1 Jin-A Jung,1 Shin-Yun Byun2*
    Original Article Allergy Asthma Immunol Res. 2014 March;6(2):126-130. http://dx.doi.org/10.4168/aair.2014.6.2.126 pISSN 2092-7355 • eISSN 2092-7363 The Effects of Inhaled Albuterol in Transient Tachypnea of the Newborn Myo-Jing Kim,1 Jae-Ho Yoo,1 Jin-A Jung,1 Shin-Yun Byun2* 1Department of Pediatrics, Dong-A University, College of Medicine, Busan, Korea 2Department of Pediatrics, Pusan National University School of Medicine, Yangsan, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose: Transient tachypnea of the newborn (TTN) is a disorder caused by the delayed clearance of fetal alveolar fluid.ß -adrenergic agonists such as albuterol (salbutamol) are known to catalyze lung fluid absorption. This study examined whether inhalational salbutamol therapy could improve clinical symptoms in TTN. Additional endpoints included the diagnostic and therapeutic efficacy of salbutamol as well as its overall safety. Methods: From January 2010 through December 2010, we conducted a prospective study of 40 newborns hospitalized with TTN in the neonatal intensive care unit. Patients were given either inhalational salbutamol (28 patients) or placebo (12 patients), and clinical indices were compared. Results: The dura- tion of tachypnea was shorter in patients receiving inhalational salbutamol therapy, although this difference was not statistically significant. The dura- tion of supplemental oxygen therapy and the duration of empiric antibiotic treatment were significantly shorter in the salbutamol-treated group.
    [Show full text]
  • Diseases of the Respiratory System (J00-J99) ICD-10-CM
    Diseases of the Respiratory System (J00-J99) ICD-10-CM Coverage provided by Amerigroup Inc. This publication contains proprietary information. This material is for informational purposes only. Reference the Centers for Medicare and Medicaid Services (CMS) for more information on Risk Adjustment and the CMS-HCC Model. Redistribution or other use is strictly forbidden This publication is for informational purposes only and is not guaranteed to be without defect. Please reference the current version(s) of the ICD-10-CM codebook, CMS-HCC Risk Adjustment Model, and AHA Coding Clinic for complete code sets and official coding guidance. AGPCARE-0080-19 63321MUPENABS 10/05/16 Diseases of the respiratory system are located in chapter Intermittent asthma which is defined as less 10 of the ICD-10-CM code book; this chapter includes than or equal to two occurrences per week. conditions such as asthma, pneumonia, and chronic Persistent asthma which includes three levels obstructive pulmonary disease (COPD). of severity: Mild: more than two times per week Reporting respiratory conditions Moderate: daily and may restrict Codes for reporting diseases of the respiratory physical activity system in ICD-10-CM feature relatively minor Severe: throughout the day with changes from ICD-9-CM. Most of the changes recurrent severe attacks limiting the involve understanding the medical terminology that ability to breathe the more specific codes include, as well as, the new The fourth character indicates severity, and the general coding structure and rules. fifth identifies whether status asthmaticus or At the beginning of chapter 10 for “Diseases of exacerbation is present. the Respiratory System (J00-J99),” an instructional note states, “When a respiratory condition is Asthma ICD-10-CM description described as occurring in more than one site and Category J45 Asthma is not specifically indexed, it should be classified Includes: to the lower anatomic site.” For example, Allergic: tracheobronchitis is classified to bronchitis with Asthma code J40.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis: a Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2
    Review Allergy Asthma Immunol Res. 2016 July;8(4):282-297. http://dx.doi.org/10.4168/aair.2016.8.4.282 pISSN 2092-7355 • eISSN 2092-7363 Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India 2Department of Respiratory Medicine, Mata Chanan Devi Hospital, New Delhi, India This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. In susceptible individuals, inhalation of Aspergillus spores can affect the respiratory tract in many ways. These spores get trapped in the viscid spu- tum of asthmatic subjects which triggers a cascade of inflammatory reactions that can result in Aspergillus-induced asthma, allergic bronchopulmo- nary aspergillosis (ABPA), and allergic Aspergillus sinusitis (AAS). An immunologically mediated disease, ABPA, occurs predominantly in patients with asthma and cystic fibrosis (CF). A set of criteria, which is still evolving, is required for diagnosis. Imaging plays a compelling role in the diagno- sis and monitoring of the disease. Demonstration of central bronchiectasis with normal tapering bronchi is still considered pathognomonic in pa- tients without CF. Elevated serum IgE levels and Aspergillus-specific IgE and/or IgG are also vital for the diagnosis. Mucoid impaction occurring in the paranasal sinuses results in AAS, which also requires a set of diagnostic criteria. Demonstration of fungal elements in sinus material is the hall- mark of AAS.
    [Show full text]
  • CT Children's CLASP Guideline
    CT Children’s CLASP Guideline Chest Pain INTRODUCTION . Chest pain is a frequent complaint in children and adolescents, which may lead to school absences and restriction of activities, often causing significant anxiety in the patient and family. The etiology of chest pain in children is not typically due to a serious organic cause without positive history and physical exam findings in the cardiac or respiratory systems. Good history taking skills and a thorough physical exam can point you in the direction of non-cardiac causes including GI, psychogenic, and other rare causes (see Appendix A). A study performed by the New England Congenital Cardiology Association (NECCA) identified 1016 ambulatory patients, ages 7 to 21 years, who were referred to a cardiologist for chest pain. Only two patients (< 0.2%) had chest pain due to an underlying cardiac condition, 1 with pericarditis and 1 with an anomalous coronary artery origin. Therefore, the vast majority of patients presenting to primary care setting with chest pain have a benign etiology and with careful screening, the patients at highest risk can be accurately identified and referred for evaluation by a Pediatric Cardiologist. INITIAL INITIAL EVALUATION: Focused on excluding rare, but serious abnormalities associated with sudden cardiac death EVALUATION or cardiac anomalies by obtaining the targeted clinical history and exam below (red flags): . Concerning Pain Characteristics, See Appendix B AND . Concerning Past Medical History, See Appendix B MANAGEMENT . Alarming Family History, See Appendix B . Physical exam: - Blood pressure abnormalities (obtain with manual cuff, in sitting position, right arm) - Non-innocent murmurs . Obtain ECG, unless confident pain is musculoskeletal in origin: - ECG’s can be obtained at CT Children’s main campus and satellites locations daily (Hartford, Danbury, Glastonbury, Shelton).
    [Show full text]
  • Right Heart Pressures in Bronchial Asthma
    Thorax: first published as 10.1136/thx.26.1.39 on 1 January 1971. Downloaded from Thorax (1971), 26, 39. Right heart pressures in bronchial asthma R. F. GUNSTONE St. George's Hospital, London S.W.1 Right heart pressures, electrocardiograms, blood gases, and peak expiratory flow rates were measured in nine patients admitted to hospital with severe bronchial asthma. Low or normal right heart pressures were found despite electrocardiographic changes in five patients consisting of right atrial P waves, abnormal right axis deviation, and in one patient T-wave changes in pre- cordial leads. These electrocardiographic changes reverted towards normal on recovery of the patient from the asthmatic attack. Electrocardiographic changes suggestive of right The procedure was carried out in the general ward heart embarrassment have been noted in acute with the patient in the sitting position supported at 60 bronchial asthma, particularly right atrial P waves to 90 degrees to the horizontal because orthopnoea (P and abnormal right axis deviation was always present. Immediately after catheterization pulmonale) the peak expiratory flow rate was measured with a (Harkavy and Romanoff, 1942; Miyamato, Wright peak flow meter (Wright and McKerrow, Bastaroli, and Hoffman, 1961; Ambiavagar, 1959) and blood (capillary or arterial) was taken for Jones and Roberts, 1967). These observations measurement of pH, Pco2, and standard bicarbonate raise the possibility that death in bronchial asthma by the Astrup method (Astrup, J0rgensen, Andersen, may be due to acute cor pulmonale although and Engel, 1960). The peak flow rate and electro- copyright. necropsy evidence is against this suggestion (Earle, cardiogram were repeated after recovery.
    [Show full text]
  • Chapter 17 Dyspnea Sabina Braithwaite and Debra Perina
    Chapter 17 Dyspnea Sabina Braithwaite and Debra Perina ■ PERSPECTIVE Pathophysiology Dyspnea is the term applied to the sensation of breathlessness The actual mechanisms responsible for dyspnea are unknown. and the patient’s reaction to that sensation. It is an uncomfort- Normal breathing is controlled both centrally by the respira- able awareness of breathing difficulties that in the extreme tory control center in the medulla oblongata, as well as periph- manifests as “air hunger.” Dyspnea is often ill defined by erally by chemoreceptors located near the carotid bodies, and patients, who may describe the feeling as shortness of breath, mechanoreceptors in the diaphragm and skeletal muscles.3 chest tightness, or difficulty breathing. Dyspnea results Any imbalance between these sites is perceived as dyspnea. from a variety of conditions, ranging from nonurgent to life- This imbalance generally results from ventilatory demand threatening. Neither the clinical severity nor the patient’s per- being greater than capacity.4 ception correlates well with the seriousness of underlying The perception and sensation of dyspnea are believed to pathology and may be affected by emotions, behavioral and occur by one or more of the following mechanisms: increased cultural influences, and external stimuli.1,2 work of breathing, such as the increased lung resistance or The following terms may be used in the assessment of the decreased compliance that occurs with asthma or chronic dyspneic patient: obstructive pulmonary disease (COPD), or increased respira- tory drive, such as results from severe hypoxemia, acidosis, or Tachypnea: A respiratory rate greater than normal. Normal rates centrally acting stimuli (toxins, central nervous system events).
    [Show full text]